LIVN Earnings

LIVN reported its earnings on 2026-05-06, showcasing a revenue of 362.30M against an estimate of 349.70M, resulting in a 3.6% surprise. The EPS was 0.98, surpassing the expected 0.9 by 36.11%. The stock experienced a 15.05% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following LIVN's earnings announcement on 2026-05-06, the stock price moved by 15.05% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, LIVN's stock price tends to shift by an average of -2.13% in the 10 days leading up to earnings and 0.12% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate LIVN's annual revenue to reach 374.77M, while the EPS is projected at 1.13. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between LIVN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, LIVN's stock price typically moves by -2.13% in the 10 days before its earnings and 0.12% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 1.13 and revenue of 374.77M.

The earnings call presents a mixed outlook: strong cardiopulmonary growth and Essenz penetration are positives, but challenges in the HGNS market and uncertainties in the epilepsy business post-reimbursement change are concerning. The Middle East conflict's impact and management's vague responses add uncertainty. The overall revenue growth and adjusted income margin projections are stable, but the lack of guidance specifics and potential market risks balance the positives. Given these factors, the stock price is likely to remain neutral in the short term.